AclarionACON
ACON
About: Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
Employees: 6
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
4.42% less ownership
Funds ownership: 4.43% [Q4 2024] → 0.01% (-4.42%) [Q1 2025]
44% less funds holding
Funds holding: 9 [Q4 2024] → 5 (-4) [Q1 2025]
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
99% less capital invested
Capital invested by funds: $66.4K [Q4 2024] → $723 (-$65.7K) [Q1 2025]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Research analyst outlook
We haven’t received any recent analyst ratings for ACON.
Financial journalist opinion
Neutral
MCAP MediaWire
6 days ago
Aclarion Adds UHealth, University of Miami Miller School of Medicine as CLARITY Trial Site
BROOMFIELD, Colo., June 10, 2025 – PRISM MediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the addition of UHealth — University of Miami Health System and the University of Miami Miler School of Medicine as a CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial site. The landmark CLARITY study is designed to demonstrate Nociscan's clinical and economic value in spine surgery.
Neutral
GlobeNewsWire
3 weeks ago
Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site
USC Spine Center, part of Keck Medicine of USC, specializes in treating complex spine conditions with the latest cutting-edge technologies CLARITY is a randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 20, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the addition of Keck Medical Center of USC as a CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial site.
Neutral
GlobeNewsWire
1 month ago
Aclarion Announces Texas Back Institute as New CLARITY Trial Site
Texas Back Institute is a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 12, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the addition of the Texas Back Institute (TBI) as a CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial site.
Neutral
MCAP MediaWire
1 month ago
Aclarion Welcomes Advocate Health as CLARITY Trial Site
Press Audio: BROOMFIELD, Colo., May 05, 2025 – PRISM MediaWire – Aclarion, Inc.
Neutral
GlobeNewsWire
1 month ago
Aclarion Welcomes Advocate Health as CLARITY Trial Site
Advocate Health actively participates in research studies and is an innovator in technology, including spine The CLARITY trial is designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 05, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the addition of Advocate Aurora Research Institute, part of Advocate Health, as a CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) site.
Neutral
GlobeNewsWire
1 month ago
Aclarion Announces Commercial Agreement with Spine Institute of Louisiana
Expands access to first customer using Philips MR Spectroscopy (MRS), demonstrating ease of Nociscan integration across multiple MRS platforms Nociscan now commercially available at 17 sites covering eight states and four countries BROOMFIELD, Colo., April 29, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today it has established a commercial agreement with the Spine Institute of Louisiana (SIL) in Shreveport, LA.
Neutral
GlobeNewsWire
1 month ago
Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025
BROOMFIELD, Colo., April 23, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025 at 12:30 PM ET.
Neutral
GlobeNewsWire
1 month ago
Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis
Independent Cost-Effectiveness Analysis Concludes Nociscan is Effective and Less Costly Compared to Provocative Discography Conclusions Illustrate Nociscan Saves $1,712 per Patient and Improves Surgical Success by 10% BROOMFIELD, Colo., April 21, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a peer-reviewed article in Clinicoeconomics and Outcomes Research titled "The Comparison of Cost-Effectiveness Between Magnetic Resonance Spectroscopy and Provocative Discography in the Identification of Chronic Low Back Pain Surgery Candidates.
Neutral
GlobeNewsWire
2 months ago
Aclarion to Present at the Planet MicroCap Showcase: VEGAS in Partnership with MicroCapClub
BROOMFIELD, Colo., April 09, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025 at 12:30 PM ET.
Neutral
MCAP MediaWire
2 months ago
Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California
MICSC are leaders in Los Angeles providing MRI and Diagnostic Imaging services MICSC expands access to Nociscan beyond Beverly Hills now available in Santa Monica Broomfield, CO, April 2, 2025 – PRISM MediaWire – Aclarion, Inc.
Charts implemented using Lightweight Charts™